Therapeutic Strategies for Cytokines

Overview

Journal Curr Opin Oncol

Specialty Oncology

Date 1995 Nov 1

PMID 8547407

Citations 2

Authors

J P Dutcher

Affiliations

Soon will be listed here.

Abstract

Cytokines have now entered the clinical arena as important mediators of the immune system and the hematopoietic system. The interleukins (ILs) in clinical trials as anticancer agents at this time include IL-1, IL-2, IL-4, IL-6 and IL-12. Other cytokines with demonstrated anticancer activity include the interferons and tumor necrosis factor. The complexity of this system is gradually being understood, and the clinical efficacy of these agents is being developed. This review is an update of the status of several of these agents in clinical investigations.

Citing Articles

Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat.

Jean W, Spellman S, Wallenfriedman M, Flores C, Kurtz B, Hall W J Neurooncol. 2004; 66(1-2):39-49.

PMID: 15015768 DOI: 10.1023/b:neon.0000013477.94568.0f.

An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells.

Eberl G, Jiang S, Yu Z, Schneider P, Corradin G, Mach J Clin Exp Immunol. 1998; 114(2):173-8.

PMID: 9822273 PMC: 1905111. DOI: 10.1046/j.1365-2249.1998.00710.x.